{"name":"Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona","slug":"azienda-ospedaliera-oo-rr-s-giovanni-di-dio-e-ruggi-d-aragona","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"azelastine hydrochloride 0.05%","genericName":"azelastine hydrochloride 0.05%","slug":"azelastine-hydrochloride-0-05","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"}]}],"pipeline":[{"name":"azelastine hydrochloride 0.05%","genericName":"azelastine hydrochloride 0.05%","slug":"azelastine-hydrochloride-0-05","phase":"marketed","mechanism":"Azelastine hydrochloride is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the nasal mucosa.","indications":["Allergic rhinitis (seasonal and perennial)","Vasomotor rhinitis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}